CYTONET SUBMITS EUROPEAN APPROVAL APPLICATION FOR LIVER CELL THERAPY TO TREAT UREA CYCLE DISORDERS IN CHILDREN

Weinheim/Germany (ots) - International biotechnology firm Cytonet
announced today that the European Medicines Agency (EMA) has
validated its Marketing Authorization Application (MAA) seeking
approval for its liver cell therapy for the treatment of Urea Cycle
Disorders (UCD) in children.

UCD is a life-threatening liver metabolism disorder which can
affect newborns and infants, causing toxic levels of ammonia to
accumulate in the body. This can lead to massive damage of the brain
and nervous system. Cytonet's liver cell therapy has the potential to
stabilize ammonia levels through infusion of healthy liver cells,
potentially increasing the length of time children can safely wait
until they can undergo a liver transplant.

"Every life we can save through Liver Cell Therapy is validation
of our company's mission. This is a very significant milestone for
us," said Dr. Wolfgang Rüdinger, Cytonet's CEO and CSO. Michael J.
Deissner, CEO and CFO added: "Currently children with UCD have few
effective treatment options. We are committed to doing what it takes
to make this therapy available to patients around the world."

Cytonet is conducting a clinical trial in the U.S. and Canada,
Safety and Efficacy of Liver Cell Application (SELICA III), designed
to test the safety and efficacy of liver cell therapy in infants to
children up to five years old with UCD. SELICA III is currently
enrolling patients at 11 sites in the United States and Canada.

ABOUT UCD AND LIVER CELL THERAPY

For parents of babies born with UCD, the joy of giving birth to a
perfect baby can quickly turn to devastation as the baby's health
rapidly declines, going from symptoms such as being tired and
irritable, to not eating, to experiencing seizures and coma.

Children left untreated for UCD rarely experience normal physical
and mental development. The only cure currently available is liver
transplantation, which can be an extremely difficult procedure for
the very young. Additionally, there is a shortage of suitable organs
available for transplantation.

Liver cell therapy involves collecting healthy cells from donated
livers not suitable for transplantation which are then gently
isolated and undergo complex processing. These cells are infused into
the portal vein over six days.

ABOUT CYTONET

Cytonet is an international biotechnology company which is located
in Weinheim and Heidelberg in Germany and in Durham, NC in the U.S.
The company develops and produces cellular products for therapeutic
purposes. Cytonet's goal is to provide alternatives to existing
therapies for many diseases with a particular emphasis on liver
diseases. Cytonet is a pioneer and leader in the field of
regenerative medicine. For the past several years, Cytonet has worked
with internationally-leading metabolism and neonatal centers to study
its liver cell therapy which uses healthy and metabolically
functional human liver cells collected from donated livers not
suitable for transplant for infusion to treat urea cycle disorders in
children. For more information, please visit Cytonet's website at
http://www.cytonetllc.com/

Contact:
Susan Donath
+49 (6201) 2598-133
presse@cytonet.de

Mary Cunney
+u1 (212) 373-6030
mcunney@golinharris.com